Last reviewed · How we verify
Human umbilical cord mesenchymal stem cell injection — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Human umbilical cord mesenchymal stem cell injection (Human umbilical cord mesenchymal stem cell injection) — Shanghai Life Science & Technology.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Human umbilical cord mesenchymal stem cell injection TARGET | Human umbilical cord mesenchymal stem cell injection | Shanghai Life Science & Technology | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Human umbilical cord mesenchymal stem cell injection CI watch — RSS
- Human umbilical cord mesenchymal stem cell injection CI watch — Atom
- Human umbilical cord mesenchymal stem cell injection CI watch — JSON
- Human umbilical cord mesenchymal stem cell injection alone — RSS
Cite this brief
Drug Landscape (2026). Human umbilical cord mesenchymal stem cell injection — Competitive Intelligence Brief. https://druglandscape.com/ci/human-umbilical-cord-mesenchymal-stem-cell-injection. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab